Results 21 to 30 of about 2,265 (188)

Tezepelumab: a promising therapy for severe uncontrolled asthma [PDF]

Exploration of Asthma & Allergy
Asthma is a complex inflammatory airway disease affecting a significant global population, spanning from childhood through adulthood. Despite advances in treatment modalities, a significant subset of patients, approximately 10%, grapple with severe ...
Argyri Klironomou, Georgia Papaiakovou, Agamemnon Bakakos, Nektarios Anagnostopoulos, Evangelia Koukaki, Efthymia Theofani, Maria Semitekolou, Nikoletta Rovina   +7 more
doaj   +2 more sources

Tezepelumab Improves Small Airways Dysfunction in Severe Asthma: A 52-Week Real-World Study. [PDF]

Clin Transl Allergy
Clinical and Translational Allergy, Volume 16, Issue 1, January 2026.
Menzella F, Cottini M, Parazzini E, Chan R, Ventura L, Mondoni M, Bosi A, Bortoli M, Senna G, Lombardi C, Corsi L, Tonin S, Rastelli A, Albrici C, Carone G, Sartor M, Piovesan TS, Marchi MR.   +17 more
europepmc   +2 more sources

Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma. [PDF]

Allergy
Allergy, Volume 81, Issue 1, Page 277-280, January 2026.
Hirai K, Uehara S, Shirai T, Akamatsu T, Itoh K.   +4 more
europepmc   +2 more sources

Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study

Allergology International, 2023
Background: Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced exacerbations by 56% compared with placebo in adults and adolescents with severe,
Tamotsu Ishizuka, Andrew Menzies-Gow, Hiroshi Okada, Yasushi Fukushima, Nobuya Hayashi, Gene Colice, Sandhia Ponnarambil, Gillian Hunter, Hiroshi Odajima, Motohiro Ebisawa   +9 more
doaj   +1 more source

Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis

Cells, 2022
The anti-thymic stromal lymphopoietin antibody (tezepelumab) has therapeutical potential for inadequately controlled asthma. However, evidence comparing tezepelumab with other biologics is scarce.
Koichi Ando, Yosuke Fukuda, Akihiko Tanaka, Hironori Sagara   +3 more
doaj   +1 more source

Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma

Allergology International, 2023
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades.
Momoko Kurihara, Hiroki Kabata, Misato Irie, Koichi Fukunaga   +3 more
doaj   +1 more source

Dramatic Response to Tezepelumab as an Initial Biologic Agent for Refractory Asthma Associated with Type 2 and Non-type 2 Traits [PDF]

, 2023
A 74-year-old Japanese woman presented with a 45-year history of refractory asthma. She had been treated with inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist for 6 months. She also had a repeated viral infection.
Hosoya, Masaharu, Hosoya, Takeshi, Kanehiro, Arihiko, Minami, Daisuke, Miyahara, Nobuaki, Nagano, Akichika, Nakajima, Yasuhiro   +6 more
core   +1 more source

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Respiratory Research, 2020
Background Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid-sparing potential of tezepelumab are being investigated in two ongoing ...
Andrew Menzies-Gow, Sandhia Ponnarambil, John Downie, Karin Bowen, Åsa Hellqvist, Gene Colice   +5 more
doaj   +1 more source

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

Respiratory Research, 2020
Background Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral corticosteroids (OCS), often at high
Michael E. Wechsler, Gene Colice, Janet M. Griffiths, Gun Almqvist, Tor Skärby, Teresa Piechowiak, Primal Kaur, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil   +10 more
doaj   +1 more source

Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study

Pulmonary Therapy, 2023
Introduction Annual influenza vaccinations are recommended for adolescents and adults with moderate to severe asthma. This study investigated the effect of tezepelumab, a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin,
Jeremy Cole, Iwona Cąpała-Szczurko, Stephanie Roseti, Claudia Chen, Scott Caveney, Anastasia A. Aksyuk, Katie Streicher, Sandhia Ponnarambil, Gene Colice   +8 more
doaj   +1 more source